IL6R and rheumatoid arthritis: Moreover, we have recently shown that in RA, treatment with tumor necrosis factor (TNF)-inhibitors and the interleukin (IL)-6 receptor (IL-6R) antagonist tocilizumab affect B cell phenotype and IgD-CD27- memory B cells in peripheral blood (19).